For Small Cell Lung Cancer, Rechallenge Chemotherapy Not Superior to Other Regimens
the Cancer Therapy Advisor take:
Rechallenge chemotherapty is not superior to other chemotherapies for patients with sensitive-relapse small cell lung cancer (SCLC), according to a Japanese study published in the American Journal of Clinical Oncology. Therefore, monotherapy such as amrubicin may be a reasonable form of second-line chemotherapy.
Researchers led by Kazushige Wakuda, PhD, from the Shizuoka Cancer Center Hospital in Japan looked at 65 patients who were assessable for efficacy and safety evaluation in order to evaluate the effect of rechallenge chemotherapy compared to those treated with other regimens in sensitive-relapse SCLC.
Endpoints were overall survival (OS), progression-free survival (PFS), and toxicity. Sensitive-relapse was defined as treatment-free intervals of 90 days or more.
They found no significant difference in OS between the rechallenge group (14.4 months) and those that were treated with other regimens (13.1 months), including amrubicin.
The researchers also found no difference in response to first-line treatment, although treatment-free intervals were significantly longer in the rechallenge group.
Rechallenge chemotherapty is not superior to other chemotherapies for patients with sensitive-relapse SCLC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma